Pulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Glendon E. French III sold 55,453 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the sale, the director now directly owns 1,011,974 shares of the company's stock, valued at $8,379,144.72. The trade was a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Pulmonx Price Performance
Shares of NASDAQ LUNG remained flat at $8.62 during mid-day trading on Friday. The company had a trading volume of 287,436 shares, compared to its average volume of 346,647. The business's fifty day moving average is $6.75 and its 200 day moving average is $6.86. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a market capitalization of $340.39 million, a price-to-earnings ratio of -5.99 and a beta of 0.64.
Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pulmonx
Several institutional investors and hedge funds have recently added to or reduced their stakes in LUNG. Deerfield Management Company L.P. Series C purchased a new stake in shares of Pulmonx in the fourth quarter valued at approximately $10,421,000. FMR LLC lifted its holdings in Pulmonx by 11.2% in the third quarter. FMR LLC now owns 5,872,882 shares of the company's stock valued at $48,686,000 after acquiring an additional 591,859 shares during the period. PFM Health Sciences LP purchased a new stake in shares of Pulmonx during the 3rd quarter worth $3,058,000. Altium Capital Management LLC grew its stake in shares of Pulmonx by 63.0% during the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company's stock worth $5,534,000 after purchasing an additional 315,000 shares during the period. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Pulmonx in the 3rd quarter valued at about $1,711,000. Institutional investors and hedge funds own 91.04% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on LUNG. Wells Fargo & Company cut their target price on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Citigroup reissued a "neutral" rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus reduced their target price on shares of Pulmonx from $17.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $12.75.
View Our Latest Stock Analysis on LUNG
Pulmonx Company Profile
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Articles
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
